Key Takeaways

• Eyconis announced the initiation of OVERTURE, a first-in-human phase 1b/2a clinical trial of EYC-0305 in patients with treatment-naïve wet AMD.
• In the trial, patients will receive a single intravitreal dose of EYC-0305 every 24 weeks, without traditional monthly loading doses.
• The goal of developing EYC-0305 is to provide durable disease control while reducing treatment burden without the need for surgery, an implant, or a device.

Eyconis announced the initiation of OVERTURE, a first-in-human clinical trial of EYC-0305 in patients with treatment-naïve wet AMD. EYC-0305 is designed to deliver sustained anti-VEGF therapy using the TransCon technology platform licensed from Ascendis Pharma for ophthalmology. The goal is to provide durable disease control while reducing treatment burden, with the potential to enable treatment intervals of 6 months or longer without the need for surgery, an implant, or a device.

The OVERTURE study is an open-label phase 1b/2a clinical trial designed to evaluate the safety and tolerability of intravitreal EYC-0305 across multiple dose levels. Patients with treatment-naïve wet AMD are expected to receive a single dose of EYC-0305 every 24 weeks, without traditional monthly loading doses. The study will also evaluate pharmacokinetics and measures of disease activity to inform the next stage of EYC-0305 clinical development, including the potential for durability beyond 6 months.

“Despite major advances in the treatment of exudative retinal diseases, there remains a significant unmet need for therapies that can safely and consistently extend dosing intervals while maintaining optimal disease control,” said Charles C. Wykoff, MD, PhD, Director of Research at Retina Consultants of Texas, investigator in the OVERTURE trial, and scientific advisor to Eyconis, in a press release from the company. “A markedly longer-acting biologic anti-VEGF [agent] delivered by standard intravitreal injection would be an important advance.”